US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CAR-T Concept

1,411.11

-24.9857-1.74%

Number of Gainers:- -

Number of Losers:2

Number of Flat:- -

PE:- -

High:1,436.79

Open:1,430.69

Low:1,408.77

Close:1,436.09

Loading ...

Director Jeffrey Bluestone Reports Disposal of Common Shares in Gilead Sciences Inc

Gilead Sciences Reaches $202 Million Settlement Over Kickback Scheme Promoting HIV Drugs

MT Newswires Live

BRIEF-NY AG James- My Office And 48 AGS Secured $202 Million From Gilead Sciences - X Post

NY Ag James- My Office and 48 Ags Secured $202 Million From Gileadsciences - X Post

THOMSON REUTERS

Gilead Sciences and Arcus Biosciences: New Lung Cancer Treatment Combinations Under Evaluation

Gilead presents new data on twice-yearly lenacapavir for HIV prevention

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for Hiv Prevention at Ias 2025

THOMSON REUTERS

Gilead price target raised to $114 from $105 at Leerink

Gilead Sciences Secures FDA Approval for Yeztugo as HIV Prevention PrEP and Pursues Accelerated Regulatory Reviews Globally

BUZZ-Leerink Partners raises PT on Gilead, citing HIV treatments prospects

WHO recommends Gilead's twice-yearly injection for HIV prevention

BRIEF-World Health Organization Recommends Injectable Lenacapavir For HIV Prevention

Who Recommends Injectable Lenacapavir for Hiv Prevention

THOMSON REUTERS

World Health Organization: Recommends Public Health Approach to Hiv Testing Using Hiv Rapid Tests to Support Delivery of Long-Acting Injectable Prep

THOMSON REUTERS

Gilead estimates Q2 acquired IPR&D expenses of $61M

Novartis Loses Patent Infringement Suit Against MSN Pharmaceuticals for Entresto Generic

MT Newswires Live

Novartis loses bid to block MSN generic of Entresto, Bloomberg says

FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports

MT Newswires Live

BRIEF-Briacell’S Bria-Imt™ Demonstrates Survival Advantage Over Trodelvy® And Control Group In Metastatic Breast Cancer

Briacell’s Bria-Imt™ Demonstrates Survival Advantage Over Trodelvy® and Control Group in Metastatic Breast Cancer

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4578/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1411.1064,"timestamp":1752609599999,"preClose":1436.0922,"halted":0,"volume":6464463,"delay":0,"changeRate":-0.017398,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-24.985718,"latestTime":"07-15 16:00:00 EDT","open":1430.6909,"high":1436.785,"low":1408.7722,"amount":723457448.580673,"amplitude":0.019506,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1752652800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.49152,"peRate":19.839762,"turnoverRate":0.00208,"increases":0,"decrements":2,"flats":0,"marketCap":370126807040,"floatMarketCap":358839156736},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1436.785,"amplitude":0.019506,"preClose":1436.0922,"low":1408.7722,"pbRate":"6.49152","latestPrice":1411.1064,"volume":6464463,"delay":0,"open":1430.6909,"prevYearClose":1164.883,"prevWeekClose":1423.4974,"prevMonthClose":1430.2296,"prevQuarterClose":1430.2296,"fiveDayClose":1436.6605,"twentyDayClose":1414.7239,"sixtyDayClose":1316.2539,"secType":"PLATE","market":"US","turnoverRate":0.00208,"peRate":19.839762,"marketCap":370126807040,"floatMarketCap":358839156736,"timestamp":1752609599999,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":0,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2551194413","title":"Director Jeffrey Bluestone Reports Disposal of Common Shares in Gilead Sciences Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2551194413","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551194413?lang=en_us&edition=fundamental","pubTime":"2025-07-16 03:59","pubTimestamp":1752609597,"startTime":"0","endTime":"0","summary":"Jeffrey Bluestone, a Director at Gilead Sciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nNDL6zSKpL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","SG9999015978.USD","IE00B3T34201.USD","LU1066053197.SGD","LU1674673428.USD","BK4578","LU0320765992.SGD","LU2087621335.USD","BK4568","SG9999015986.USD","LU1066051498.USD","BK4139","LU0289739699.SGD","IE00B19Z3B42.SGD","LU0234570918.USD","LU1839511570.USD","BK4588","IE00BKVL7J92.USD","BK4550","BK4566","LU2324357040.USD","SG9999015945.SGD","BK4583","BK4532","BK4585","GILD","IE0002270589.USD","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","SG9999015952.SGD","IE00BZ1G4Q59.USD","LU0058720904.USD","LU2089984988.USD","LU2468319806.SGD","LU0109394709.USD","LU1674673691.USD","LU1778281490.HKD","LU1430594728.SGD","IE00B19Z3581.USD","LU1585245621.USD","LU0889565916.HKD","LU0823416689.USD"],"gpt_icon":0},{"id":"2551194848","title":"Gilead Sciences Reaches $202 Million Settlement Over Kickback Scheme Promoting HIV Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2551194848","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551194848?lang=en_us&edition=fundamental","pubTime":"2025-07-16 03:04","pubTimestamp":1752606251,"startTime":"0","endTime":"0","summary":"Gilead Sciences (GILD) has agreed to pay $202 million to settle claims that it violated US anti-kickback laws through its HIV drug speaker programs, according to a Tuesday statement by New York Attorn","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","IE00BZ1G4Q59.USD","BK4585","IE00B3T34201.USD","LU1778281490.HKD","LU1585245621.USD","LU1674673428.USD","GILD","LU2087621335.USD","LU2468319806.SGD","SG9999015945.SGD","SG9999015978.USD","BK4566","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0823416689.USD","IE00BSNM7G36.USD","LU0234570918.USD","LU1430594728.SGD","BK4550","BK4139","IE00BKVL7J92.USD","LU1839511570.USD","LU1066051498.USD","LU0320765992.SGD","LU2324357040.USD","LU0109394709.USD","SG9999015952.SGD","SG9999015986.USD","BK4568","LU1571399168.USD","LU0058720904.USD","BK4532","BK4578","LU2089984988.USD","IE0002270589.USD","IE00B19Z3581.USD","BK4583","LU1066053197.SGD","BK4588","LU1674673691.USD"],"gpt_icon":0},{"id":"2551196293","title":"BRIEF-NY AG James- My Office And 48 AGS Secured $202 Million From Gilead Sciences - X Post","url":"https://stock-news.laohu8.com/highlight/detail?id=2551196293","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551196293?lang=en_us&edition=fundamental","pubTime":"2025-07-16 00:30","pubTimestamp":1752597003,"startTime":"0","endTime":"0","summary":"BRIEF-NY AG James- My Office And 48 AGS Secured $202 Million From Gilead Sciences - X PostJuly 15 (Reuters) - Gilead Sciences Inc GILD.O:NY AG JAMES- MY OFFICE AND 48 AGS SECURED $202 MILLION FROM GILEADSCIENCES - X POSTSource https://tinyurl.com/ymr5t6ca ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nFWN3TC13A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","BK4588","IE0002270589.USD","LU0889565916.HKD","LU2087621335.USD","LU2089984988.USD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU1674673428.USD","SG9999015945.SGD","IE00B3T34201.USD","LU1778281490.HKD","LU1839511570.USD","LU1674673691.USD","LU0823416689.USD","BK4578","LU2324357040.USD","LU1585245621.USD","LU2468319806.SGD","LU1066051498.USD","LU0058720904.USD","LU0234570918.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","IE00B19Z3B42.SGD","SG9999015952.SGD","BK4566","LU1066053197.SGD","LU1430594728.SGD","LU0109394709.USD","GILD","LU1571399168.USD","BK4568","LU0289739699.SGD","BK4532","SG9999015986.USD","BK4585","LU0320765992.SGD","BK4139","IE00BSNM7G36.USD","SG9999015978.USD","BK4583"],"gpt_icon":0},{"id":"2551196281","title":"NY Ag James- My Office and 48 Ags Secured $202 Million From Gileadsciences - X Post","url":"https://stock-news.laohu8.com/highlight/detail?id=2551196281","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551196281?lang=en_us&edition=fundamental","pubTime":"2025-07-16 00:30","pubTimestamp":1752597002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nFWN3TC13A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4578","LU1674673428.USD","BK4588","IE00B19Z3B42.SGD","BK4568","LU1430594728.SGD","LU1674673691.USD","IE00BSNM7G36.USD","SG9999015978.USD","LU0109394709.USD","BK4550","SG9999015945.SGD","IE00B19Z3581.USD","LU2468319806.SGD","LU0234570918.USD","LU0058720904.USD","SG9999015986.USD","BK4139","BK4566","BK4532","BK4583","BK4585","IE0002270589.USD","IE00BZ1G4Q59.USD","LU1778281490.HKD","LU2087621335.USD","LU0289739699.SGD","IE00B3T34201.USD","LU1585245621.USD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU0889565916.HKD","LU0320765992.SGD","LU1066053197.SGD","LU0823416689.USD","LU2089984988.USD","SG9999015952.SGD","LU1571399168.USD","LU2324357040.USD","GILD","LU1839511570.USD","LU1066051498.USD"],"gpt_icon":0},{"id":"2551180988","title":"Gilead Sciences and Arcus Biosciences: New Lung Cancer Treatment Combinations Under Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2551180988","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551180988?lang=en_us&edition=fundamental","pubTime":"2025-07-15 00:01","pubTimestamp":1752508913,"startTime":"0","endTime":"0","summary":"Gilead Sciences (($GILD)), Arcus Biosciences (($RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. The V...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gilead-sciences-and-arcus-biosciences-new-lung-cancer-treatment-combinations-under-evaluation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gilead-sciences-and-arcus-biosciences-new-lung-cancer-treatment-combinations-under-evaluation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1066051498.USD","BK4578","BK4566","IE00B3T34201.USD","LU0058720904.USD","LU0234570918.USD","LU2087621335.USD","LU2089984988.USD","IE0002270589.USD","BK4532","IE00B19Z3B42.SGD","BK4139","SG9999015986.USD","LU1430594728.SGD","GILD","LU1066053197.SGD","BK4550","SG9999015978.USD","IE00B19Z3581.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU0823416689.USD","LU0289739699.SGD","LU2324357040.USD","LU0320765992.SGD","LU1674673691.USD","BK4568","IE00B7SZLL34.SGD","LU1571399168.USD","SG9999015945.SGD","LU1585245621.USD","BK4585","LU1839511570.USD","LU2468319806.SGD","LU1778281490.HKD","LU0109394709.USD","IE00BKVL7J92.USD","BK4583","LU1674673428.USD","SG9999015952.SGD","LU0889565916.HKD","BK4588"],"gpt_icon":0},{"id":"2551184925","title":"Gilead presents new data on twice-yearly lenacapavir for HIV prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2551184925","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551184925?lang=en_us&edition=fundamental","pubTime":"2025-07-14 21:35","pubTimestamp":1752500110,"startTime":"0","endTime":"0","summary":"Gilead (GILD) Sciences announced that Gilead researchers and collaborators will present new Phase 3 PURPOSE trial data at IAS 2025 showing that twi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-presents-new-data-on-twice-yearly-lenacapavir-for-hiv-prevention-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-presents-new-data-on-twice-yearly-lenacapavir-for-hiv-prevention-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B7SZLL34.SGD","SG9999015945.SGD","LU1674673428.USD","LU1778281490.HKD","LU1066051498.USD","LU1571399168.USD","GILD","BK4585","LU1839511570.USD","SG9999015986.USD","LU1066053197.SGD","LU0320765992.SGD","IE00BSNM7G36.USD","BK4009","BK4568","LU2089984988.USD","BK4583","LU2324357040.USD","BK4588","IAS","LU2087621335.USD","LU1674673691.USD","LU0823416689.USD","BK4539","BK4566","LU0058720904.USD","BK4139","LU0234570918.USD","BK4578","LU1585245621.USD","SG9999015978.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4550","BK4532","LU0109394709.USD","SG9999015952.SGD","LU0889565916.HKD","IE00B3T34201.USD","LU0289739699.SGD","LU1430594728.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2551771181","title":"Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for Hiv Prevention at Ias 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2551771181","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551771181?lang=en_us&edition=fundamental","pubTime":"2025-07-14 21:30","pubTimestamp":1752499800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nTUASMMKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0289739699.SGD","BK4588","SG9999015978.USD","IE00BZ1G4Q59.USD","LU1571399168.USD","LU1066051498.USD","LU2468319806.SGD","BK4532","GILD","IE00B19Z3B42.SGD","BK4550","IE00BKVL7J92.USD","LU1674673691.USD","IE00BSNM7G36.USD","LU0234570918.USD","LU1778281490.HKD","LU0823416689.USD","BK4566","LU1839511570.USD","LU1066053197.SGD","IE00B7SZLL34.SGD","LU0058720904.USD","LU2087621335.USD","LU1585245621.USD","IE00B19Z3581.USD","BK4568","LU0109394709.USD","LU2089984988.USD","SG9999015945.SGD","BK4583","IE00B3T34201.USD","BK4585","SG9999015952.SGD","BK4139","LU0889565916.HKD","LU0320765992.SGD","SG9999015986.USD","BK4578","LU2324357040.USD","IE0002270589.USD","LU1430594728.SGD","LU1674673428.USD"],"gpt_icon":0},{"id":"2551181958","title":"Gilead price target raised to $114 from $105 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2551181958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551181958?lang=en_us&edition=fundamental","pubTime":"2025-07-14 21:06","pubTimestamp":1752498406,"startTime":"0","endTime":"0","summary":"Leerink analyst David Risinger raised the firm’s price target on Gilead (GILD) to $114 from $105 and keeps an Outperform rating on the shares. The ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-price-target-raised-to-114-from-105-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-price-target-raised-to-114-from-105-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3B42.SGD","LU0889565916.HKD","LU1674673691.USD","IE00BZ1G4Q59.USD","LU1066053197.SGD","LU0320765992.SGD","BK4566","SG9999015952.SGD","BK4583","GILD","LU0234570918.USD","SG9999015978.USD","LU2087621335.USD","BK4550","LU1839511570.USD","IE0002270589.USD","IE00BKVL7J92.USD","LU1585245621.USD","LU2468319806.SGD","LU0289739699.SGD","LU1066051498.USD","BK4585","BK4139","BK4588","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LU0823416689.USD","SG9999015986.USD","SG9999015945.SGD","LU1430594728.SGD","LU1778281490.HKD","LU2324357040.USD","LU0058720904.USD","BK4532","LU1571399168.USD","IE00B3T34201.USD","BK4568","LU1674673428.USD","IE00BSNM7G36.USD","LU0109394709.USD","LU2089984988.USD","BK4578"],"gpt_icon":0},{"id":"2551554189","title":"Gilead Sciences Secures FDA Approval for Yeztugo as HIV Prevention PrEP and Pursues Accelerated Regulatory Reviews Globally","url":"https://stock-news.laohu8.com/highlight/detail?id=2551554189","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551554189?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:31","pubTimestamp":1752496270,"startTime":"0","endTime":"0","summary":"Gilead Sciences Inc. has received approval from the U.S. Food and Drug Administration  for Yeztugo as PrEP to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg. This approval marks a significant step in HIV prevention efforts. Additionally, Gilead has submitted applications for marketing authorization and EU-M4all with the European Medicines Agency  for the same medication, which are under expedited review. The company is also seeking regulatory approval for twice-yearly lenacapavir as PrEP in several countries, including Australia, Brazil, Canada, South Africa, and Switzerland, with plans for further filings in Argentina, Mexico, and Peru. This development aligns with Gilead's strategic partnership with The Global Fund to supply lenacapavir at no profit to reach up to two million people in supported countries over the next three years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL9Djws4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","BK4583","BK4139","SG9999015986.USD","LU0889565916.HKD","BK4532","LU0289739699.SGD","BK4588","IE00B19Z3B42.SGD","SG9999015978.USD","LU1066051498.USD","IE00BKVL7J92.USD","IE00B3T34201.USD","GILD","SG9999015952.SGD","LU0058720904.USD","BK4568","LU1674673428.USD","LU1674673691.USD","BK4550","LU1066053197.SGD","LU0320765992.SGD","IE00BZ1G4Q59.USD","LU0234570918.USD","BK4566","LU2087621335.USD","LU1778281490.HKD","BK4585","LU1839511570.USD","LU2468319806.SGD","IE00B19Z3581.USD","LU0109394709.USD","LU1430594728.SGD","LU2324357040.USD","SG9999015945.SGD","IE00B7SZLL34.SGD","LU1571399168.USD","LU2089984988.USD","LU0823416689.USD","IE00BSNM7G36.USD","IE0002270589.USD","BK4578"],"gpt_icon":0},{"id":"2551690747","title":"BUZZ-Leerink Partners raises PT on Gilead, citing HIV treatments prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2551690747","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551690747?lang=en_us&edition=fundamental","pubTime":"2025-07-14 18:38","pubTimestamp":1752489536,"startTime":"0","endTime":"0","summary":"BUZZ-Leerink Partners raises PT on Gilead, citing HIV treatments prospects** Brokerage Leerink Partners raises PT on drugmaker Gilead Sciences GILD.O to $114 from $105 ** Brokerage says it does not anticipate any \"major top- or bottom-line surprises\" in GILD's earnings, ahead of its Q2 results likely to be reported in early August** Maintains \"outperform\" rating** The new price target represents a 3.97% upside to the stock's last close** Aside from earnings, brokerage says \"the central focus will be on two recent HIV PrEP and treatment pipeline developments\" ** Brokerage says GILD's recently approved twice-yearly injectable HIV PrEP, Yeztugo, can quickly and widely become available, considering its lower price compared to its once-daily PrEP drug, Descovy, and its efficacy even though unclear guidelines after U.S. top court ruling on preventative coverage and CMS ** Twenty of 30 brokerages rate the stock \"buy\" or higher, 10 \"hold\"; their median PT is $118.50 - data compiled by LSEG** U","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nL4N3TB0TF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","BK4566","BK4583","LU0289739699.SGD","LU1585245621.USD","IE00B7SZLL34.SGD","BK4585","LU0320765992.SGD","BK4532","LU2468319806.SGD","LU0109394709.USD","LU1066053197.SGD","BK4568","SG9999015978.USD","LU2324357040.USD","SG9999015945.SGD","SG9999015952.SGD","SG9999015986.USD","LU1778281490.HKD","LU0889565916.HKD","LU1674673691.USD","IE00B19Z3581.USD","GILD","LU1066051498.USD","BK4550","BK4139","LU0058720904.USD","IE00BKVL7J92.USD","BK4588","LU0823416689.USD","LU1430594728.SGD","LU1571399168.USD","LU2089984988.USD","LU1839511570.USD","LU2087621335.USD","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","BK4578","LU1674673428.USD","IE00B3T34201.USD"],"gpt_icon":0},{"id":"2551909203","title":"WHO recommends Gilead's twice-yearly injection for HIV prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2551909203","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551909203?lang=en_us&edition=fundamental","pubTime":"2025-07-14 17:10","pubTimestamp":1752484246,"startTime":"0","endTime":"0","summary":"WHO recommends Gilead's twice-yearly injection for HIV preventionJuly 14  - The World Health Organization on Monday recommended Gilead's  GILD.O lenacapavir, a twice-yearly injection, for preventing HIV infection.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nL4N3TB0O6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015945.SGD","BK4578","IE00B7SZLL34.SGD","LU1585245621.USD","BK4550","LU2087621335.USD","SG9999015952.SGD","LU1430594728.SGD","LU2324357040.USD","LU1066051498.USD","LU0058720904.USD","LU1674673691.USD","LU0234570918.USD","LU1571399168.USD","SG9999015978.USD","BK4566","LU0109394709.USD","LU1778281490.HKD","BK4583","LU1674673428.USD","LU2089984988.USD","LU0289739699.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","BK4588","BK4139","BK4585","IE00BKVL7J92.USD","LU1839511570.USD","IE0002270589.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU0823416689.USD","SG9999015986.USD","BK4532","LU2468319806.SGD","IE00B3T34201.USD","LU0320765992.SGD","BK4568","GILD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2551172909","title":"BRIEF-World Health Organization Recommends Injectable Lenacapavir For HIV Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2551172909","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551172909?lang=en_us&edition=fundamental","pubTime":"2025-07-14 17:03","pubTimestamp":1752483838,"startTime":"0","endTime":"0","summary":"BRIEF-World Health Organization Recommends Injectable Lenacapavir For HIV PreventionJuly 14  - World Health Organization:WHO RECOMMENDS INJECTABLE LENACAPAVIR FOR HIV PREVENTIONWORLD HEALTH ORGANIZATION: RECOMMENDS PUBLIC HEALTH APPROACH TO HIV TESTING USING HIV RAPID TESTS TO SUPPORT DELIVERY OF LONG-ACTING INJECTABLE PREPFurther company coverage: GILD.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3TA01I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00B19Z3581.USD","LU0823416689.USD","BK4550","LU2468319806.SGD","IE00B19Z3B42.SGD","LU1571399168.USD","BK4578","LU1778281490.HKD","IE00B7SZLL34.SGD","LU0320765992.SGD","SG9999015945.SGD","BK4139","BK4568","LU1585245621.USD","LU2324357040.USD","SG9999015978.USD","BK4532","SG9999015952.SGD","IE00B3T34201.USD","LU0058720904.USD","LU0289739699.SGD","LU1674673691.USD","LU0889565916.HKD","LU1674673428.USD","BK4585","LU0109394709.USD","LU1066051498.USD","BK4583","GILD","LU1430594728.SGD","LU1066053197.SGD","LU1839511570.USD","IE00BKVL7J92.USD","LU2089984988.USD","IE00BZ1G4Q59.USD","SG9999015986.USD","LU0234570918.USD","IE0002270589.USD","IE00BSNM7G36.USD","LU2087621335.USD","BK4588"],"gpt_icon":0},{"id":"2551909364","title":"Who Recommends Injectable Lenacapavir for Hiv Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2551909364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551909364?lang=en_us&edition=fundamental","pubTime":"2025-07-14 17:00","pubTimestamp":1752483653,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3TA01I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B3T34201.USD","BK4139","LU2324357040.USD","IE00BKVL7J92.USD","LU1674673691.USD","LU2089984988.USD","LU0823416689.USD","BK4566","LU2087621335.USD","LU0109394709.USD","LU1066051498.USD","IE00BZ1G4Q59.USD","LU2468319806.SGD","LU0889565916.HKD","LU0234570918.USD","LU1674673428.USD","SG9999015945.SGD","BK4568","IE00BSNM7G36.USD","SG9999015978.USD","LU0320765992.SGD","GILD","IE00B19Z3B42.SGD","BK4578","SG9999015986.USD","BK4585","LU1839511570.USD","BK4583","LU1778281490.HKD","LU0058720904.USD","SG9999015952.SGD","LU1430594728.SGD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU1585245621.USD","LU1571399168.USD","LU0289739699.SGD","LU1066053197.SGD","BK4550","BK4532","BK4588","IE0002270589.USD"],"gpt_icon":0},{"id":"2551096869","title":"World Health Organization: Recommends Public Health Approach to Hiv Testing Using Hiv Rapid Tests to Support Delivery of Long-Acting Injectable Prep","url":"https://stock-news.laohu8.com/highlight/detail?id=2551096869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551096869?lang=en_us&edition=fundamental","pubTime":"2025-07-14 17:00","pubTimestamp":1752483653,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3TA01I:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1066053197.SGD","BK4550","LU2324357040.USD","LU1066051498.USD","SG9999015952.SGD","LU0109394709.USD","LU1778281490.HKD","GILD","LU0289739699.SGD","BK4532","LU2089984988.USD","SG9999015945.SGD","BK4588","IE00B19Z3581.USD","LU1674673428.USD","IE00B7SZLL34.SGD","LU1674673691.USD","BK4578","LU0889565916.HKD","LU0058720904.USD","LU1571399168.USD","BK4585","LU0234570918.USD","LU0823416689.USD","LU0320765992.SGD","LU2468319806.SGD","LU1839511570.USD","IE00B19Z3B42.SGD","LU2087621335.USD","LU1585245621.USD","IE00B3T34201.USD","SG9999015978.USD","BK4568","BK4566","LU1430594728.SGD","IE00BKVL7J92.USD","IE0002270589.USD","IE00BSNM7G36.USD","SG9999015986.USD","IE00BZ1G4Q59.USD","BK4583"],"gpt_icon":0},{"id":"2550577964","title":"Gilead estimates Q2 acquired IPR&D expenses of $61M","url":"https://stock-news.laohu8.com/highlight/detail?id=2550577964","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550577964?lang=en_us&edition=fundamental","pubTime":"2025-07-12 05:15","pubTimestamp":1752268510,"startTime":"0","endTime":"0","summary":"For the second quarter of 2025, Gilead (GILD) currently expects $61M in acquired IPR&D expenses, representing a charge of roughly 4c to both GAAP a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-estimates-q2-acquired-iprd-expenses-of-61m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-estimates-q2-acquired-iprd-expenses-of-61m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1571399168.USD","BK4139","LU0109394709.USD","IE00B19Z3B42.SGD","IE0002270589.USD","IE00BKVL7J92.USD","BK4566","IE00B7SZLL34.SGD","LU0889565916.HKD","IE00BSNM7G36.USD","LU2087621335.USD","BK4578","BK4585","BK4532","GILD","IE00B19Z3581.USD","LU1839511570.USD","LU0320765992.SGD","LU0234570918.USD","LU1674673428.USD","SG9999015986.USD","BK4550","LU2468319806.SGD","SG9999015978.USD","LU0823416689.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","LU1066051498.USD","LU2089984988.USD","BK4583","LU1066053197.SGD","LU2324357040.USD","SG9999015952.SGD","IE00B3T34201.USD","BK4588","LU1430594728.SGD","LU1674673691.USD","BK4568","LU1778281490.HKD","SG9999015945.SGD","LU0058720904.USD","LU1585245621.USD"],"gpt_icon":0},{"id":"2550965666","title":"Novartis Loses Patent Infringement Suit Against MSN Pharmaceuticals for Entresto Generic","url":"https://stock-news.laohu8.com/highlight/detail?id=2550965666","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550965666?lang=en_us&edition=fundamental","pubTime":"2025-07-12 02:33","pubTimestamp":1752258819,"startTime":"0","endTime":"0","summary":"Novartis  has lost a lawsuit that accused MSN Pharmaceuticals of infringing on its patent for chronic heart failure treatment drug Entresto, according to a federal court decision in Delaware published Friday.MSN Pharmaceuticals will be allowed to manufacture and sell a generic version of Novartis' drug, according to a decision from US District Judge Richard Andrews.The patent for the drug expires on November 8, 2026, the court document said.Novartis said it was \"disappointed\" and plans to appeal the decision, the company said in an emailed statement to MT Newswires.MSN Pharmaceuticals did not immediately reply to a request for comment from MT Newswires.Novartis shares were down 2% in recent trading.Price: 121.29, Change: -2.44, Percent Change: -1.97","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B4R5TH58.HKD","BK4532","LU0208291251.USD","NVS","IE00BJT1NW94.SGD","BK4578","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4007","BK4585","LU0211331839.USD","LU0320765489.SGD","IE00B2B36J28.USD","IE0009355771.USD","MSN","IE00BFTCPJ56.SGD","LU0070302665.USD","BK4588","BK4078"],"gpt_icon":0},{"id":"2550470957","title":"Novartis loses bid to block MSN generic of Entresto, Bloomberg says","url":"https://stock-news.laohu8.com/highlight/detail?id=2550470957","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550470957?lang=en_us&edition=fundamental","pubTime":"2025-07-11 23:35","pubTimestamp":1752248125,"startTime":"0","endTime":"0","summary":"11:30 EDT Novartis (NVS) loses bid to block MSN generic of Entresto, Bloomberg says Published first on TheFly – the ultimate source for real-time, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-loses-bid-to-block-msn-generic-of-entresto-bloomberg-says-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-loses-bid-to-block-msn-generic-of-entresto-bloomberg-says-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","BK4588","MSN","IE00B4R5TH58.HKD","LU0320765489.SGD","BK4007","IE0009355771.USD","BK4078","NVS","IE00B2B36J28.USD","LU0211331839.USD","BK4578","IE00BJJMRZ35.SGD","BK4585","IE00BFTCPJ56.SGD","LU0070302665.USD","BK4532","LU0208291251.USD","IE0002141913.USD"],"gpt_icon":0},{"id":"2550954696","title":"FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2550954696","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550954696?lang=en_us&edition=fundamental","pubTime":"2025-07-11 22:25","pubTimestamp":1752243928,"startTime":"0","endTime":"0","summary":"Price: 25.55, Change: -0.23, Percent Change: -0.89","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B3PB1722.GBP","JNJ","LU0306807586.USD","LU1069344957.HKD","LU2129689605.HKD","LU1674673691.USD","LU2552382058.USD","SG9999014567.USD","LU1221951046.USD","IE00BN8TJ469.HKD","IE00BVYPNW00.USD","LLY","LU2237443549.SGD","IE00BFXG0V08.USD","LU0265550359.USD","IE00BJLML261.HKD","LU1934455277.USD","LU2462157665.USD","SG9999014575.USD","LU1093756168.USD","PFE","GSK","LU0965509010.AUD","LU2237443978.SGD","NVS","LU2461242641.AUD","LU1023059063.AUD","AZN","LU1935042991.SGD","LU2237438978.USD","LU0203345920.USD","LU1988902786.USD","LU1074936037.SGD","LU2129689514.USD","LU1066051225.USD","LU0965509101.SGD","GSK.UK","IE00BFTCPJ56.SGD","LU2361044865.SGD","LU1267930813.SGD","BK4578","LU2505996509.AUD","IE00BGHQF631.EUR","MRK","LU2491049909.HKD","LU0070302665.USD","LU1778281490.HKD","FAST","LU0912757837.SGD"],"gpt_icon":0},{"id":"2550958392","title":"BRIEF-Briacell’S Bria-Imt™ Demonstrates Survival Advantage Over Trodelvy® And Control Group In Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2550958392","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550958392?lang=en_us&edition=fundamental","pubTime":"2025-07-11 19:33","pubTimestamp":1752233609,"startTime":"0","endTime":"0","summary":"BRIEF-Briacell’S Bria-Imt Demonstrates Survival Advantage Over Trodelvy And Control Group In Metastatic Breast CancerJuly 11 (Reuters) - Briacell Therapeutics Corp BCT.TO:BRIACELL’S BRIA-IMT DEMONSTRA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nTUA3NNDR9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BCTXZ","LU1066053197.SGD","BK4568","LU0289739699.SGD","LU2087621335.USD","BK4532","LU1430594728.SGD","LU1839511570.USD","IE00B3T34201.USD","LU2324357040.USD","BK4588","SG9999015986.USD","BK4578","LU0058720904.USD","IE00B19Z3B42.SGD","BK4585","BK4139","LU1585245621.USD","BK4550","LU2468319806.SGD","GILD","IE00BSNM7G36.USD","LU0823416689.USD","BK4566","LU0320765992.SGD","LU1674673691.USD","LU1571399168.USD","LU0889565916.HKD","LU1066051498.USD","IE00BZ1G4Q59.USD","BCTXW","BK4583","IE00B7SZLL34.SGD","LU1778281490.HKD","SG9999015978.USD","LU0234570918.USD","SG9999015945.SGD","IE0002270589.USD","IE00B19Z3581.USD","LU2089984988.USD","IE00BKVL7J92.USD","SG9999015952.SGD","LU1674673428.USD"],"gpt_icon":0},{"id":"2550295838","title":"Briacell’s Bria-Imt™ Demonstrates Survival Advantage Over Trodelvy® and Control Group in Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2550295838","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550295838?lang=en_us&edition=fundamental","pubTime":"2025-07-11 19:30","pubTimestamp":1752233451,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nTUA3NNDR9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1066051498.USD","SG9999015945.SGD","LU0289739699.SGD","LU0889565916.HKD","LU0109394709.USD","BK4585","LU1674673691.USD","IE00BZ1G4Q59.USD","SG9999015986.USD","IE0002270589.USD","LU1585245621.USD","LU1778281490.HKD","LU0234570918.USD","LU0823416689.USD","LU2089984988.USD","SG9999015978.USD","GILD","LU2087621335.USD","BK4583","LU2468319806.SGD","IE00B7SZLL34.SGD","BK4139","LU1571399168.USD","BK4568","IE00BSNM7G36.USD","LU1674673428.USD","BK4566","LU1430594728.SGD","BK4550","IE00B19Z3B42.SGD","BCTXW","LU1066053197.SGD","IE00BKVL7J92.USD","LU0320765992.SGD","LU2324357040.USD","SG9999015952.SGD","LU0058720904.USD","BK4578","IE00B19Z3581.USD","BK4532","IE00B3T34201.USD","BK4588","BCTXZ","LU1839511570.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}]}}